A review of the pharmacology of carbonic anhydrase inhibitors for the treatment of glaucoma in dogs and cats
详细信息 查看全文
- 作者：Tomasz Maślanka ; tomasz.maslanka@uwm.edu.pl" class="auth_mail" title="E-mail the corresponding author
- 关键词：Carbonic anhydrase inhibitors ; Glaucoma ; Intraocular pressure ; Canine ; Feline
- 刊名：The Veterinary Journal
- 出版年：2015
- 出版时间：March 2015
- 年：2015
- 卷：203
- 期：3
- 页码：278-284
- 全文大小：351 K
文摘
- •
Topical 2% dorzolamide is a safe and effective intraocular pressure (IOP) lowering agent in dogs and cats.
- •
Dorzolamide can be used in the treatment of both primary and secondary glaucoma in dogs and cats.
- •
Dorzolamide should be considered as the first-line therapy for feline glaucoma.
- •
Topical carbonic anhydrase inhibitors (CAIs) do not cause systemic side effects, but can cause ocular side effects.
- •
Systemic CAIs are also effective in lowering IOP, but their clinical application is limited by their systemic toxicity.